Starpharma Holdings Limited (SPHRF) Stock Price & Analysis
SPHRF Stock Chart & Stats
- Day’s Range
- $0.33 - $0.33
- 52-Week Range
- $0.16 - $0.63
- Previous Close
- $0.33
- Volume
- 1,000
- Average Volume (3M)
- 42
- Market Cap
- $152.75M
- Enterprise Value
- $284.34M
- Total Cash (Recent Filing)
- $11.02M
- Total Debt (Recent Filing)
- $707.00K
- Price to Earnings (P/E)
- ―
- Beta
- 0.40
- Next Earnings
- Mar 02, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Debt Reduction
Material debt reduction lowers financial risk and reduces the burden of interest and refinancing obligations. This gives Starpharma greater resilience while it develops its dendrimer-based products, although continued losses mean the balance-sheet benefit must be preserved.
Improved Cash Burn
The marked improvement in operating and free cash outflows indicates progress in controlling cash consumption. While Starpharma remains cash-flow negative, a lower burn rate can extend funding capacity and provide more time for products and partnerships to generate commercial returns.
Gross Profit Generation
A substantial gross profit contribution shows that Starpharma’s commercial activities can generate value above direct product costs. Converting that gross profit into operating profitability remains unresolved, but the underlying product economics provide a base for future scaling and expense leverage.
Bears Say
Persistent Losses
Sustained operating and net losses show that Starpharma has not yet established a self-sustaining earnings model. Continued losses can consume capital, restrict investment flexibility, and make future progress dependent on achieving stronger revenue scale or materially improving operating costs.
Negative Free Cash Flow
Persistent negative free cash flow means the business is not currently funding its operations and development needs internally. Even with improved 2026 cash burn, ongoing outflows may require additional funding unless profitability improves, creating a durable constraint on strategic flexibility.
Equity Erosion
The substantial decline in equity indicates that cumulative losses and cash use have reduced Starpharma’s financial resources. A smaller asset base limits flexibility relative with earlier years and leaves less balance-sheet capacity to absorb setbacks or support extended product development.
SPHRF FAQ
What was Starpharma Holdings Limited’s price range in the past 12 months?
What is Starpharma Holdings Limited’s market cap?
When is Starpharma Holdings Limited’s upcoming earnings report date?
How were Starpharma Holdings Limited’s earnings last quarter?
Is Starpharma Holdings Limited overvalued?
Does Starpharma Holdings Limited pay dividends?
What is Starpharma Holdings Limited’s EPS estimate?
How many shares outstanding does Starpharma Holdings Limited have?
What happened to Starpharma Holdings Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Starpharma Holdings Limited?
What is the TipRanks Smart Score and how is it calculated?
Starpharma Holdings Limited Stock Smart Score
Company Description
Starpharma Holdings Limited
Starpharma Holdings Limited is a biopharmaceutical enterprise focused on the research, development, and global commercialization of dendrimer-based products for the pharmaceutical, life sciences, and other industries. Its current offerings include VivaGel, a non-antibiotic treatment and preventative measure for bacterial vaginosis. The company also provides the antiviral VivaGel condom and VIRALEZE, an antiviral nasal spray. Furthermore, Starpharma is actively progressing its DEP (dendrimer drug delivery) technology platform. This platform supports multiple oncology candidates in clinical development, such as DEP docetaxel (Phase 2), DEP cabazitaxel (Phase 2), DEP gemcitabine (Phase 1/2), and DEP irinotecan (Phase 2), all aimed at treating cancer. The DEP technology is also being applied to radiotheranostics for cancer diagnosis and therapy, Antibody Drug Conjugates (including DEP HER-2 ADC), and non-oncology programs. Additionally, DEP AZD0466 is currently in Phase 1/2 clinical trials for haematological malignancies. Founded in 1996, the company maintains its headquarters in Abbotsford, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Cheryl Maley
- Employees
- 50
- Website
- starpharma.com
- Address
- Suite 3.02, Richmond, VIC, 3121, AU
Starpharma Holdings Limited (SPHRF) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 1 | 14 |
| Technical Analysis | 6 | 1 | 3 |
| Moving Averages | 1 | 0 | 11 |